文献速递前列腺癌男科与性医学

泌尿外科临床试验成功与失败的预测因素

Clinical Trials in Urology: Predictors of Successes and Failures.
PubMed 文献 · J Urol · 2020-04-07

该研究检索ClinicalTrials.gov 2006至2016年泌尿外科试验,最终纳入1,340项(成功722项,失败618项),用多因素logistic回归分析失败相关因素。结果显示肿瘤、不孕/男科、器械试验及多源资助与失败相关,失败主因是招募不足(41%)。

要点

  • 肿瘤亚专业试验失败风险增高(AOR 2.25)。
  • 不孕/男科试验失败风险最高(AOR 4.99)。
  • 招募不足占失败原因的41%。

核心结论

  • 许多泌尿外科试验因招募不足而提前失败。
  • 肿瘤、男科/不孕、器械及多区域试验的成功障碍显著。

研究设计与样本

  • 检索ClinicalTrials.gov 2006至2016年泌尿外科试验,由2名筛选者筛选,争议由第三方裁决。
  • 共1,340项试验符合纳入标准(成功722项,失败618项)。
  • 采用Fisher精确检验、卡方检验和Wilcoxon秩和检验进行单变量分析,多变量logistic回归分析失败相关因素。

主要发现

  • 肿瘤亚专业与失败相关(AOR 2.25,95%CI 1.60-3.18)。
  • 不孕/男科亚专业与失败相关(AOR 4.99,95%CI 1.60-17.61)。
  • 器械试验与失败相关(AOR 1.64,95%CI 1.00-2.70)。
  • 工业/政府/资助组合资助与失败相关(AOR 3.13,95%CI 2.21-4.48)。
  • AUA分会的试验比国际和多区域试验更不易失败。

关键数值与推荐

  • 失败试验中招募不足占41%。
  • 失败其他原因:预算不足9%、申办方取消7%、中期结果不佳7%、毒性3%。

临床怎么用

  • 设计泌尿外科试验时应优先评估招募可行性,尤其肿瘤、男科/不孕和器械领域。
  • 多源资助和多区域试验需更谨慎规划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clinical trials serve as a critical source of information to guide evidence-based practices in urology. Conversely, trials that are abandoned consume significant resources and results are underreported in the literature. MATERIALS AND METHODS: ClinicalTrials.gov was queried for urology trials from 2006 to 2016. Trials were screened by 2 screeners for applicability to urology and disputes were resolved by a third independent reviewer. Overall 1,340 trials met final inclusion criteria (722 successful trials, 618 failed trials). Univariable analysis used Fisher's exact, chi-squared and Wilcoxon rank sum tests. Trial characteristics, including AUA (American Urological Association) section, phase, subspecialty, intervention type, source of funding and randomization were examined for association with failure using multivariable logistic regression. RESULTS: Trial failure is associated with oncology subspecialty (adjusted odds ratio 2.25, 95% CI 1.60-3.18), infertility/andrology subspecialty (AOR 4.99, CI 1.60-17.61), device trials (AOR 1.64, CI 1.00-2.70) and combination funding by industry/government/grants (AOR 3.13, CI 2.21-4.48). Clinical trials in AUA sections were less likely to fail than international and multisectional trials. Among trials that failed, poor accrual was the primary reason for trial failure, comprising 41% of all failures. Other reasons for failure include inadequate budget (9%), sponsor cancellation (7%), poor interim results (7%) and toxicity (3%). CONCLUSIONS: Despite their significance, many urological trials fail prematurely due to poor accrual. Complex features inherent to oncology, andrology/infertility, devices and multisectional trials pose significant barriers to success.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Bandari J, Theisen KM, Maganty A, et al. Clinical Trials in Urology: Predictors of Successes and Failures. J Urol. 2020. PMID: 32267191. doi:10.1097/JU.0000000000001072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。